Abivax Email Format
Biotechnology ResearchÎle-de-france, France51-200 Employees
Abivax is a clinical-stage biotechnology company based in Paris, France, focusing on therapeutics that harness the body's natural regulatory mechanisms to stabilize immune responses in chronic inflammatory diseases. Its lead candidate, obefazimod, is in Phase 3 trials for moderately to severely active ulcerative colitis, with plans to initiate a Phase 2a trial in Crohn's disease. Obefazimod is an orally administered, once-daily therapy believed to enhance the expression of microRNA-124, a natural regulator of the inflammatory response, potentially forming a new class of miR-124 enhancers. The company operates in the biotechnology research industry and employs between 51 and 200 people. Its address is 7-11 Boulevard Haussmann, Paris, Île-de-france 75009 France.